Maksim Petrov

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.

Black Knight (NYSE:BKI) is a leading provider of integrated software, data and analytics solutions that facilitate and automate many of the business processes across the homeownership life cycle.

Black Knight is committed to being a premier business partner that clients rely on to achieve their strategic goals, realize greater success and better serve their customers by delivering best-in-class software, services and insights with a relentless commitment to excellence, innovation, integrity and leadership.

Our name, 2seventy bioTM, is inspired by the maximum speed of translating human thought into action — 270 miles per hour. At 2seventy bio, we think in the language of time. It’s about timeTM we endeavor to outmaneuver cancer so the people we serve can have the chance for MORE…more time building stories with families and friends, experiencing their passions, and living their best lives in the big and small moments. Too many have lost time to cancer and we are wildly impatient to help change that.

It’s about time is also the restlessness we have to change the status quo and challenge ourselves to look at things from different perspectives. And we know that it’s about time we change our workplaces into human places that allow us to dream big, devise solutions, and deliver new therapies that are designed with the goal to "think" smarter and faster than cancer.

At 2seventy bio, we have the benefit of time and experience that we apply to our endeavors. We carry with us a legacy of deep care for patients and our people, thought leadership, learnings, and scientific expertise from our gene therapy and oncology roots. We build upon this strong foundation with our extensive knowledge in cell therapy, our expanding and robust research pipeline, and our vast experience across the continuum of drug development and commercialization.

And our time spent with collaborators is crucial. We work closely with patients, care partners, advocacy organizations, healthcare professionals, academic, and industry partners because we know we’re better together. It is this mindset and approach that will propel us forward because we know that time matters — every day, every minute, every second — to people living with cancer.

China Life Insurance (Overseas) Company Limited, a wholly owned subsidiary of China Life Insurance (Group) Company which is the largest state-owned financial insurance corporation in China, is the strategic headquarter for overseas business development of the parent company. The parent company has been taking firm strides to develop modern insurance services and realize the “China Life Dream” of becoming a premier international financial insurance group. And with strong support from the parent company, China Life Insurance (Overseas) Company Limited has already built business networks in Hong Kong, Macau, Singapore and Indonesia. In order to set a strong foothold in those markets and establish more presences globally in the long run, China Life Insurance (Overseas) Company Limited develops constantly by means of transition, innovation and integration. The primary focus of the Company is the enhancement of profits and creation of value through organic growth as well as mergers and acquisitions. In addition, the Company puts equal emphasis on business development and investment management. The Company is not only the international business platform of the parent company but also a training center for the management team. With talented professionals, advanced technology, strong management, stable growth and excellent performance, the Company aims at becoming an industry leader in Hong Kong, Macau, Singapore and Indonesia.